Why Horizon Therapeutics Public Limited Company [HZNP] Stock Will Fly to $123.00 Over the Next 12 Months

Horizon Therapeutics Public Limited Company [HZNP] stock is up 2.42 while the S&P 500 has fallen -0.06% on Thursday, 12/03/20. While at the time of this article, HZNP ATR is sitting at 3.13, with the beta value at 1.12. This stock’s volatility for the past week remained at 4.14%, while it was 4.46% for the past 30-day period. HZNP has risen $1.68 from the previous closing price of $69.54 on volume of 3.32 million shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 3, December 2020, Horizon Therapeutics plc Provides $1 Million in Scholarships to Help Economically Disadvantaged Students and Students of Color Further Their Liberal Arts and Health Professions Education. According to news published on Yahoo Finance, Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has provided $500,000 in scholarships to Lake Forest College and created a $500,000 Horizon Therapeutics Endowed Scholarship Fund at Howard University. The scholarships at both institutions will be awarded to economically disadvantaged students and students of color.

Analyst Birdseye View:

The most recent analyst activity for Horizon Therapeutics Public Limited Company [NASDAQ:HZNP] stock was on August 27, 2020, when it was Initiated with a Buy rating from Citigroup, which also raised its 12-month price target on the stock to $112. Before that, on September 09, 2020, JP Morgan Recapitulated an Overweight rating and elevated its amount target to $110. On January 08, 2020, Goldman Initiated a Neutral rating and boosted its price target on this stock to $35. On September 26, 2019, BofA/Merrill Initiated a Buy rating and increased its price target to $34. On September 12, 2019, Guggenheim Initiated a Buy rating. On August 14, 2019, BMO Capital Markets Upgrade an Outperform rating and boosted its amount target on this stock to $36. On May 01, 2019, Citigroup Upgrade a Buy rating and boosted its target amount on this stock from $21 to $32. On March 08, 2019, Morgan Stanley Upgrade an Overweight rating and improved its amount target to $32.

In the past 52 weeks of trading, this stock has oscillated between a low of $23.81 and a peak of $86.67. Right now, according to Wall Street analyst the average 12-month amount target is $105.55. At the most recent market close, shares of Horizon Therapeutics Public Limited Company [NASDAQ:HZNP] were valued at $71.22. According to the average price forecast, investors can expect a potential return of 6.79%.


Horizon Therapeutics Public Limited Company [NASDAQ:HZNP] most recently reported quarterly sales of 636.43 billion, which represented growth of 89.70%. This publicly-traded organization’s revenue is $1,083,358 per employee, while its income is $477,517 per employee. This company’s Gross Margin is currently 74.40%, its Operating Margin is 15.00%, its Pretax Margin is -1.56, and its Net Margin is +44.08. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at 13.35, 35.38, 4.28 and 17.54 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 39.11 and the whole liability to whole assets at 31.64. It shows enduring liability to the whole principal at 38.99 and enduring liability to assets at 0.32 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 69.33 points at 1st support level, the second support level is making up to 67.43. But as of 1st resistance point, this stock is sitting at 72.22 and at 73.21 for 2nd resistance point.

Horizon Therapeutics Public Limited Company [HZNP] reported its earnings at $1.74 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at $0.97/share signifying the difference of 0.77 and 79.40% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were $0.4 calling estimates for $0.36/share with the difference of 0.04 depicting the surprise of 11.10%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Horizon Therapeutics Public Limited Company [NASDAQ:HZNP] is 3.50. Likewise, the Quick ratio is also the same, showing Cash ratio at 1.49. Now if looking for a valuation of this stock’s amount to sales ratio it’s 5.71, it’s amount to book ratio is 3.11 and showing 19.45 of P/E (TTM) ratio.

Insider Stories

The most recent insider trade was by McHugh Miles W, Sr VP & Princ. Acctg Officer, and it was the sale of 12124.0 shares on Nov 12. Camardo Daniel A., the EVP and President, U.S., completed a sale of 3500.0 shares on Nov 06. On Nov 05, MOZE BARRY, EVP, Chief Admin. Officer, completed a sale of 77500.0 shares.